# Multiple Ascending Dose Study of HM12460A in Type 2 Diabetes Mellitus

> **NCT03332836** · PHASE1 · TERMINATED · sponsor: **Hanmi Pharmaceutical Company Limited** · enrollment: 21 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **BIOLOGICAL:** HM12460A

## Key facts

- **NCT ID:** NCT03332836
- **Lead sponsor:** Hanmi Pharmaceutical Company Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-10-25
- **Primary completion:** 2019-01-30
- **Final completion:** 2020-09-30
- **Target enrollment:** 21 (ACTUAL)
- **Why stopped:** Sopnsor decision
- **Last updated:** 2021-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03332836

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03332836, "Multiple Ascending Dose Study of HM12460A in Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT03332836. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*